Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial.

Date publication

septembre 2016

Journal

BMC immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FOUYSSAC Fanny , Dr OJEDA-URIBE Mario

Tous les auteurs :
Viallard JF, Agape P, Barlogis V, Cozon G, Faure C, Fouyssac F, Gaud C, Gourin MP, Hamidou M, Hoarau C, Husseini F, Ojeda-Uribe M, Pavic M, Pellier I, Perlat A, Schleinitz N, Slama B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27687879

Résumé

Although Hizentra is indicated for immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies, phase III trials have focused on patients with primary immunodeficiencies. In this 9-month, real-life, prospective, non-interventional, longitudinal, multicenter study of patients with primary and secondary immunodeficiencies in France, treatment modalities (primary endpoint), efficacy, safety, tolerability, quality of life, and treatment satisfaction were evaluated using descriptive statistics.

Référence

BMC Immunol.. 2016 Sep;17(1):34